38
Participants
Start Date
October 13, 2016
Primary Completion Date
May 30, 2017
Study Completion Date
June 22, 2017
Talazoparib
Talazoparib 1 mg orally once daily.
Orlando Health, Inc., Orlando
Memorial Cancer Institute at Memorial Regional Hospital, Hollywood
Memorial Regional Hospital, Hollywood
Memorial Hospital West, Pembroke Pines
Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne
Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne
Ronald Reagan UCLA Medical Center, Drug Information Center, Los Angeles
TRIO-US Central Administration, Los Angeles
UCLA Hematology/Oncology, Los Angeles
UCLA West Medical Pharmacy. Attn: Steven L. Wong, Pharm.D., Los Angeles
Torrance Health Association, DBA Torrance Memorial Physician Network/Cancer Care Associates, Redondo Beach
UCLA Hematology/Oncology - Santa Monica, Santa Monica
UCLA Hematology/Oncology - Pasadena, Pasadena
UCLA Hematology/Oncology - Porter Ranch, Porter Ranch
UCLA Hematology/Oncology - Santa Clarita, Valencia
UCLA Hematology/Oncology - Burbank, Burbank
St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare, Fullerton
CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center, Bakersfield
UCLA West Medical Pharmacy, Attn: Steven L. Wong, Pharm.D., Los Angeles
Lead Sponsor
Collaborators (1)
Medivation, Inc.
INDUSTRY
Pfizer
INDUSTRY